Although the BAX/BCL-2 ratio remained constant, these findings highlight the potential of SAF as a promising candidate for further study in the development of cancer therapies, particularly targeting cervical cancer HeLa cells. The gene discussed is BCL2; the disease is cervical carcinoma.